Create Account

Ward Weight Loss®

618 E South St, Orlando, Fl 32801

*Individual results may vary.

15% body weight loss based on the average weight loss in three 68-week clinical trials of patients on Wegovy without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

In a 72-week Zepbound (tirzepatide) study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo. In a 72-week Zepbound (tirzepatide) study of adults with diabetes, average weight loss was 12.8% (28 lbs) for 10 mg, 14.7% (33 lbs) for 15 mg, and 3.2% (7 lbs) for placebo.

In a 3-year Saxenda study, adults with pre-diabetes and BMI ≥30 or ≥27 with one or more weight-related conditions were given Saxenda or placebo added to a reduced-calorie meal plan and increased physical activity. At year one, 56% of people on Saxenda lost ≥5% of their weight vs 25% of patients on placebo.

In certain situations, where clinically appropriate, a provider may prescribe compounded medication, which is prepared by a state-licensed sterile compounding pharmacy partner.

Although compounded drugs are permitted to be prescribed under federal law, they are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality.

**Insurance assistance is a benefit check conducted by a Ward Weight Loss third-party pharmacy partner to help determine potential insurance coverage for GLP-1 medications.

†Weight Loss Money-Back Guarantee: We’re so confident you’ll succeed, that if you participate in our Complete and Total Weight Management Program and don’t lose at least 10% of your body weight, you may be eligible for a refund.

Create Account

This website uses cookies.